抗体：免疫偶联物与自体细胞治疗急性淋巴细胞白血病

icartab

Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
抗体：免疫偶联物与自体细胞治疗急性淋巴细胞白血病
摘要:
使用一个57岁患有复发难治性初期B淋巴细胞急性白血病的患者为研究案例，本文探讨了使用免疫偶联物和自体细胞治疗治疗急性淋巴细胞白血病。三种治疗方案：新型免疫疗法blinatumomab，抗肿瘤药物Inotuzumab以及CAR-T细胞，每一种方案在特殊的临床情况下均有其优点，这些疗法代表了一些令人振奋的进展，在过去的几年里已经取得了治疗效果。
Abstract
Using a case study of a 57-year-old man with relapsed/refractory precursor-B (pre-B) acute lymphoblastic leukemia (ALL), this review discusses treatment with immunoconjugates and autologous therapy in acute ALL. Three therapies-blinatumomab, inotuzumab, and CAR T cells-are considered here, each with advantages in specific clinical situations. These therapies represent some of the exciting advances that have been made in the treatment of ALL over the last several years.
KEYWORDS:
ALL; Acute lymphoblastic leukemia; Antibody; BiTE; Blinatumomab; CAR; Chimeric antigen receptor; Inotuzumab
出自爱康得生物技术